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http://dx.doi.org/10.1016/j.ahj.2017.04.005Several epidemiologic data showed that the prevalence
of type 2 diabetes mellitus (T2DM) has reached epidemic
proportions worldwide. The progressive increase in food
intakes, the greater availability of refined grains, and
sedentary lifestyles exert an adverse impact on the risk of
new-onset T2DM. It is expected that the number of people
suffering from T2DM will double in the period 2000-2030.1
The most important increase in the incidence of T2DM is
expected in developing countries, where the prevalence of
obesity is also rapidly increasing. Unlike developing
countries, in the United States and Europe, the higher
prevalence of T2DM is mainly related to the increased life
expectancy of the general adult population andpatientswith
T2DM. In Italy, the Casale Monferrato Study reported an
increased rate of T2DMof approximately 45% (2.6% vs 3.8%)
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Volume 189in the period 1988-2000.2 This was particularly related to
aging, as the prevalence of T2DM increasedmainly in the age
group N65 years; of note, a doubling of the prevalence at the
age≥80 yearswas recorded. The pathophysiology of T2DM
is multifactorial as, beyond genetic background, several
acquired risk factors contribute to the development of
new-onset T2DM including prediabetic states (ie, impaired
fasting glycemia and impaired glucose tolerance), over-
weight/obesity, dyslipidemia, and arterial hypertension.3
T2DM is associated with a high risk of long-term
complications, which increase with the duration of
hyperglycemia. They can be divided into nonvascular
and vascular complications, the latter including micro-
vascular (ie, nephropathy, retinopathy, and neuropathy)
and macrovascular (ie, coronary, cerebrovascular and
peripheral arterial diseases)4 complications.
Renal dysfunction and T2DM
Worsening of kidney function is a peculiar feature of
patients suffering from T2DM. It has been shown that the
annual decline of estimated glomerular filtration rate
(eGFR) in patients with T2DM is about 2.0-2.5 mL/min
per year.5 The Renal Insufficiency And Cardiovascular
Events (RIACE) Italian Multicentre Study showed that
nonalbuminuric renal impairment is the predominant
clinical phenotype in T2DM patients, particularly women
with reduced eGFR, and that the nonalbuminuric form is
associated with a significant prevalence of cardiovascular
disease, especially at the level of the coronary vascular
bed.6,7 A recent prospective, observational study8 showed
that in a cohort of 1,682 T2DM patients with preserved
renal function (ie, eGFR ≥60 mL/min per 1.73 m2)
who were followed up for 10 years, the decline of eGFR
was −0.6 ± 0.1 mL min−1 y−1 in patients with normal
albuminuria rising to −2.7 ± 0.4 mL min−1 y−1 in those
with macroalbuminuria at baseline. The authors also found
that together with abnormal albuminuria, older age,
hypertension, insulin treatment, and lower baseline eGFR
were the strongest predictors of annual eGFR decline in
this population.8
Chronic kidney disease (CKD) has also a negative
prognostic impact in patients with T2DM. The FIELD study,
which included 9,795T2DMpatients, showed that a reduced
eGFR and the presence of albuminuria were independent
predictors of renal and cardiovascular mortality.9
Aspirin, eicosanoids, and kidney
(dys)function
Aspirin is an effective antithrombotic agent that inhibits
the production of thromboxane (Tx) A2 and other
prostaglandins by blocking the enzyme cyclooxygenase
(COX) 1. The antiplatelet action of acetylsalicylic acid
(ASA) is via specific inhibition of COX-1 through an
irreversible acetylation of serine-529 of COX-1. Thisenzyme exerts both COX(converting arachidonate into
prostaglandin G2) and peroxidase activities (converting
prostaglandin G2 into PGH2, the biochemical precursor
of many other prostaglandins and Tx). Inhibition of
COX-1 by aspirin results in complete inhibition of the
proaggregating TxA2. As platelets are anucleated, such
aspirin-induced TxA2 inhibition can be fully restored only
through the synthesis of new platelets, that is, after
approximately 7 days from aspirin administration. Previ-
ous randomized clinical trials have shown that aspirin is
effective as an antithrombotic agent at a dosage ranging
from 50 to 1500 mg/d. In patients treated with low-dose
aspirin, serum TxB2 levels are the most reliable marker of
COX-1 inhibition. Patrono et al10 have investigated the
relationship between the aspirin dose and TxB2 levels,
showing that a single dose of 100 mg reduces by 98% the
1-hour concentration of serum TxB2. Notably, serum
TxB2 returned to normal levels after a period compatible
with the platelet half-life. Urinary levels of TxB2
metabolites such as 11-dehydro-TxB2 and 2.3-dinor-TxB2
reflect the production of TxB2 in whole body.
11Because
11-dehydro-TxB2 is excreted in higher amounts and has
a longer half-life, its analysis in urine is largely used for
clinical purpose.12-14 Thromboxane binding to its
receptor expressed by platelets, smooth muscle cells,
endothelium, and vessels may exert vasoconstriction
and platelet aggregation.15
It is noteworthy that urinary 11-dehydro-TxB2 levels
reflect platelet activation in T2DM patients and is largely
dependent on glycemic control.16
In the kidney, COX enzymes exert their physiologic
regulatory functions in the macula densa, medulla, and
interstitium.17 The products of COX enzymes, and in
particular the balance between Tx and prostacyclin
production, are crucial for kidney homeostasis.18 Experi-
mental studies showed that in the macula densa, COX
enzymes favor renin production and are involved in the
regulation of renal blood flow. In particular, in animal
models, the administration of either aspirin or Tx receptor
inhibitorswas associatedwith improvements in renal plasma
flow and eGFR values, suggesting a pathogenic role for Tx
in the progression of renal damage.19-22 A previous study in
kidneys from diabetic rats has also demonstrated that an
imbalance between TxA2 and prostacyclin production
could favor the onset of diabetic nephropathy.19 Further-
more, a higher urinary Tx/prostacyclin ratiowas also found
in patients with T2DM as compared with healthy
volunteers.23
Moreover, a recent cross-sectional study performed in
115 patients with stage 1-4 CKD showed that urinary
levels of 11-dehydro-TxB2 were significantly higher in
stage 3-4 patients as compared with stage 1-2.24
To date, however, the data available in the literature on the
long-term effects of low-dose aspirin (or other antiplatelet
agents) on kidney function and progression of CKD in
humans are scarce and inconclusive.
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physicians, aspirin intake significantly reduced the risk
for decline in kidney function compared with those who
never use it in the group of subjects without cardiovas-
cular risk factors.25
In a study including 14 patients with severe congestive
heart failure, the administration of picotamide, which is a
TxA2 synthase and TxA2/prostaglandin H2 receptor
inhibitor, resulted in an improvement in effective renal
plasma flow and eGFR.26
In a retrospective cohort study of 3,585 patients with
CKD undergoing cardiac surgery, it has been reported that
preoperative aspirin use was associated with a significant
decrease in postoperative acute kidney injury.27
In a recent observational cohort study, involving 800
patients with nonvalvular atrial fibrillation,29 we found
that the use of aspirin (100 mg/d) was significantly
associated with a reduced risk of CKD progression over
2 years of follow-up. In particular, patients who were not
receiving aspirin had a 3-fold higher risk of progressing to
an eGFR value b45 mL/min per 1.73 m2 at the end of
follow-up compared with those treated with aspirin.
Furthermore, levels of urinary 11-dehydro-TxB2 excretion
were inversely associated with the aspirin use, and
strongly predicted the annual eGFR decline during the
2-year follow-up period.
Of note, in the First United Kingdom Heart and Renal
Protection (UK-HARP-I) study, which randomized 448
CKD patients to receive treatment with simvastatin
20 mg or aspirin 100 mg, allocation to treatment with
100 mg of aspirin daily was not associated with an excess
of major bleeds, suggesting that the use of low-dose
aspirin may be safe in CKD patients.28
Aspirin and renal function in T2DM
The efficacy and safety of aspirin as an antithrombotic
agent has been assessed both in apparently healthy
people at low risk for cardiovascular complications
(primary prevention) and in patients at high risk, such
as those with a prior myocardial infarction or ischemic
stroke (secondary prevention). Patients with T2DM
represent an important group of patients in whom
treatment with aspirin should be carefully considered.
The evidence that T2DM patients without previous
cardiovascular events have similar cardiovascular risk
compared with nondiabetic individuals with prior
myocardial infarction could make the use of aspirin as
primary prevention strategy for cardiovascular diseases in
this clinical setting reasonable. However, although there
is consolidated evidence about the use of aspirin for
secondary prevention in patients with T2DM, there is no
evidence of an effective use for primary cardiovascular
prevention30,31; thus, currently, the use of aspirin in this
specific group of T2DM patients remains largely at
physician discretion.4However, aspirinmay exert effects beyond cardiovascular
prevention in T2DM32; for instance, some authors investi-
gated the relationship between aspirin administration and
renal function in T2DM providing conflicting evidence.
A randomized trial including 76 patients with diabetic
nephropathy showed that short-term use of high-dose
aspirin (1000 mg) was able to reduce the rate of proteinuria
by the 15.9% as compared with control group, with no
adverse effects related to the use of aspirin.33
A Swedish cohort study34 that investigated the decline
of renal function at 5-7 years in 801 patients with CKD
showed that chronic administration of aspirin was
associated with a slower decline of renal function
compared with untreated patients (mean difference of
0.8 mL/min per 1.73 m2). The authors reported that this
beneficial effect of aspirin was maintained also in the
group of patients with diabetic nephropathy.
Conversely, the JPAD2 cohort study showed no effect
of aspirin on kidney function in 2,536 Japanese patients,
but the allocation of patients to aspirin (81 mg or 100 mg
daily) or not was at physician discretion.35
Primary end point
The aim of the study is to evaluate the decline of renal
function, as assessed by absolute change in eGFR,
calculated as the difference between eGFR at 12 months
and baseline eGFR, in T2DM patients receiving low-dose
aspirin (100 mg/d) or placebo.Secondary end points
The followingwill be considered as secondary end points:
- The rapid decline in renal function, defined as a
reduction of eGFR ≥5 mL/min at 1 year
- Change of renal function class (from G1 to G2, from
G2 to G3a, and so on) at 12 months, dialysis, or
transplantation
- Urinary 11-dehydro-TxB2 levels at the end of the follow-up
to be correlated with renal function modificationsStudy design
This is a phase 3, no-profit, multicenter, double-blind,
placebo-controlled, randomized, intervention trial of
1-year treatment with aspirin 100 mg/dvs placebo in
patients with T2DM. The inclusion and exclusion criteria
are specified in Table I. Table II reports the timeline of
events and assessments. In all participants, the following
data will be collected:
- anthropometric/clinical data (at each visit): age,
gender, height, weight, body mass index, waist
circumference, systolic and diastolic blood pressure,
heart rate;
Table I. Inclusion and exclusion criteria of the LEDA trial
Inclusion criteria
Diagnosis of type 2 diabetes43,44:
- Random blood glucose ≥200 mg/dL (≥11.1 mmol/L)
- Fasting blood glucose ≥126 mg/dL (≥7.0 mmol/L).
Fasting is defined as no caloric intake for at least 8 h.⁎
- Blood glucose 2 h after oral glucose tolerance test
(75 g OGTT) ≥200 mg/dL. The test should be
performed as described by the WHO, using a glucose
load containing the equivalent of 75 g anhydrous
glucose dissolved in water.⁎
- Hemoglobin A1c ≥6.5% (≥48 mmol/mol). The test
should be performed in a laboratory using a method
that is NGSP certified and standardized to the DCCT
assay.⁎
- Treatment with any glucose-lowering agent
Exclusion criteria
(1) History of cardiovascular or cerebrovascular events (defined on history
and/or instrumental findings provided by the patient)
(2) Presence of inadequate glycemic control (ie, hemoglobin A1c ≥8%)
(3) Presence of uncontrolled blood pressure despite antihypertensive
treatment (≥140/≥85 mm Hg)
(4) Previous major bleeding (ie, intracranial)
(5) Previous gastrointestinal ulcer
(6) Clinical diagnosis of type 1 diabetes (diagnosis of diabetes and insulin
use before age 35 y)
(7) Patients with CKD G4 or G5 stage (ie, eGFR b30 mL/min per 1.73 m2
or dialysis)
(8) Chronic active infections or
(9) Evidence of malignancy in the last 5 y. Patients with in situ neoplastic
disease successfully treated only with local excision can be included in
the study (including in situ nonmelanoma skin cancer).
(10) Autoimmune systemic diseases
(11) Sustained cardiac arrhythmias requiring anticoagulant treatment (ie,
atrial fibrillation). In this category, isolated ventricular/supraventricular
extrasystoles are not included.
(12) Use of nonsteroidal anti-inflammatory drugs, or other antiplatelet
agents in the previous 30 days
(13) Cirrhosis of any etiology
(14) Use of anticoagulants
(15) Life expectancy b1 y
(16) Known allergy to aspirin
(17) Known pregnancy
(18) Severe psychiatric illness
Abbreviations:OGTT, Oral glucose tolerance test;WHO, World Health Organization;
NGSP, National Glycohemoglobin Standardization Program; DCCT, Diabetes Control
and Complications Trial.
⁎ In the absence of unequivocal hyperglycemia, results should be confirmed by repeat testing
Table II. LEDA trial—timeline of visits and events
vent/Assessment(s)
Baseline
visit
6-mo
visit
12-mo
visit
formed consent X
clusion/exclusion X
nthropometric/clinical data X X X
edical history and concomitant treatments X
andomization X
aboratory analysis X X X
ssessment of kidney function X X X
rine sample collection and TxB2 assessment X X X
tudy drug administration X X
ithdrawal of the medication package and
compliance monitoring
X X
dverse event monitoring X X
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Volume 189- medical history (at baseline visit): diabetes duration,
cardiovascular risk factors such as smoking, alcohol
intake, dyslipidemia, arterial hypertension,36 heart
failure,37 metabolic syndrome,38 chronic obstructive
pulmonary disease39;E
In
In
A
M
R
L
A
U
S
W
A- use of all concomitant medications (at each visit):
name and daily dosage of all medications taken by
patients; and
- blood analysis (at each visit): serum creatinine
(measured using a Jaffe ́rate–blanked and compensat-
ed assay), urea nitrogen, complete blood count, fasting
glucose, insulin (only for patients not treated with
insulin), hemoglobin A1c, serum liver enzymes (ami-
notransferases and γ-glutamyltransferase), total cho-
lesterol, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, triglycerides, uric
acid, C-reactive protein (high-sensitivity C-reactive
protein), albuminuria on a morning urine sample (at
each visit).
According to albuminuria levels, patients will be
classified into 3 groups: (1) b30, (2) 30-299, and (3)
≥300 mg/g. Measurements of urine and blood parame-
ters ratio will be made with standard laboratory methods
in each single center.Estimation of kidney function
To estimate kidney function, eGFR will be calculated by the
CKD–Epidemiology Collaboration formula.40 Patients will be
classified into 4 categories based on eGFR according to the
Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines: normal eGFR (N 90 mL/min per 1.73 m2, stage
G1), mild decrease in eGFR (89-60 mL/min per 1.73 m2, stage
G2), mild-moderate decrease in eGFR (59-45 mL/min per
1.73 m2, stage G3a), moderate to severe decrease in eGFR
(44-30 mL/minper 1.73m2,G3b stage), and severedecreaseof
eGFR (b30 mL/min per 1.73 m2, stage G4).Data collection
Each investigator will collect the data and fill them in a
certified electronic platform. Each center will be
provided with personal login procedures for direct
entry of individual patient data. Investigators will be
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held until the end of the trial. Each investigator will be
provided with a sequential numerical code (01, 02, etc),
which will be used to identify the participating center at
the time of filling in the electronic platform. Patients
enrolled will be enumerated according to the order of
enrollment. For example, the first patient from the center
01 will be identified with code “01-01,” the second with
the code “01-02,” and so on. The promoter center
(Sapienza University of Rome) will require further
clarification of the data entered (eg, in the case of
incorrect insertion), but will not require any information
enabling the identification of the patient enrolled.Collection of biological samples
and measurement of urinary
11-dehydro-TxB2
Urine samples (10 mL each visit for each patient) will
be collected in all participants in the morning between
8:00 and 9:00 AM after an overnight fast. The urine
samples will be stored at −80 °C until use. The levels of
urinary 11-dehydro-TxB2 will be measured centrally (at
the promoter center) using a commercial ELISA kit
(Cayman Chemical, Ann Arbor, MI).41 The data will be
expressed as ng/mg urinary creatinine. Urinary creatinine
will be also centrally measured using a commercial
enzyme immunoassay kit.Informative sheet and informed consent
At enrollment, an investigator will explain to each
patient the modalities and the aim of the trial. Each
patient will then be asked to provide written informed
consent before the inclusion in the study. It will be also
specified that each participant is allowed to withdraw at
any time and to be informed about results at the end of
the study. The trial will be conducted in accordancewith
the Standards of Good Clinical Practice (ICH-GCP), as
expected by current regulations concerning clinical
trials and the protection of personal data (Administrative
Order; June 30, 2003; No. 196), and according to what
established by the Declaration of Helsinki (version of the
59nd WMA General Assembly, Seoul, October 2008). In
addition, an informative letter for the general practition-
er will be delivered to each patient. The study protocol
has been approved by the coordinating center's ethic
committee (Ref. 4338/2017) and, thereafter, by the
ethics committee of each center outside the Policlinico
Umberto I “Sapienza” University Hospital. Moreover, the
study protocol has been approved by the Italian
Medicine Agency (AIFA). The study protocol has been
registered at the ClinicalTrials.gov (NCT02895113) and
at the European Clinical Trials Database (EudraCT
number 2015-005231-40).Treatment delivery
All patients will be randomly assigned to either aspirin
100 mg/d or placebo (Figure) to be taken after lunch (in
nonfasting conditions) according to the randomization list.
At baseline (T0 visit), an amount of tablets for 6 monthswill
be delivered; then, patients will be reevaluated by an
investigator (T6 visit) who will assess the presence of any
adverse effect occurred during treatment or contraindica-
tion to continue the study. The investigator will also verify
the adherence to the assigned treatment by thewithdrawal
of drug bottle/empty placebo. Any error in the assumption
of the drug by the patient (ie, a reported early depletion of
tablets or the presence of residual tablets in the container)
must be promptly notified by the investigator at the
promoter center, which will assess in each case whether
such errors compromise the continuation of the study for
the patient. At T6, the investigator will give the patient the
vial containing pills necessary for the rest of the study, until
the 12-month visit (T12 visit).Randomization list
The randomization list will be generated by software and
will bemanaged by the promoter center thatwill assign the
codes for all patients at eachparticipating center in order of
enrollment. An operator who will not be involved in
patients' recruitment, or in data analysiswill be in charge of
code assignment and maintenance of randomization list in
a safe place not accessible to other investigators.Management and monitoring of
participating centers
Each participating center will receive all study mate-
rials, including the study protocol and synopsis, the case
report forms (T0, T6, T12), the information sheet, and
informed consent for the patient, as well as the approval
of the ethics committee of the promoter center, a letter of
intent to the local ethics committees, and a letter for the
general practitioners. Two investigator meetings are
being planned; the first meeting will be held before the
start of enrolments to explain the scientific rationale and
the modalities of the study and the second to assess the
state of enrollment. We will also plan to carry out in each
center, after its activation, a site visit to check (1) the
ability to conduct the study (approval if it will be obtained
a copy of the local ethics committee and viewed the
informed consent of the patients enrolled), (2) proper
data collection, and (3) the adequate storage of the
biological samples. A form of relating to each center the
evaluation after the visit will then be filled in. The
participating centers will be required to retain all
documentation relating to the study for the entire
duration of the study, and thereafter for at least
10 years, and send it to the promoter center if needed.
Figure
The LEDA trial design.
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In the case of any adverse event occurring during the
trial, it is mandatory for the investigator to report it
promptly to the promoter center. The major adverse
events that should be reported include the following:
A. Adverse effects associated with the drug treatment:
a. any occurrence of allergic reactions after taking
the tablet;
b. any gastrointestinal symptoms (eg, nausea,
heartburn);
c. any major or minor bleeding (clinically significant);
and
d. others.
B. Intercurrent disease/conditions that may be a contrain-
dication to the continuation of the trial by the patient:
a. any ischemic heart disease event (angina pectoris,
acute myocardial infarction, cardiac revasculari-
zation procedures);
b. any acute erebrovascular event (ischemic stroke,
transient ischemic attack);
c. any need to take anti-inflammatory drugs or
antiplatelet drugs for more than 1 week; and
d. other (eg, pregnancy, immobilization from
accident traumas).
Each investigator is requested to contact the promoter
center in the case of any doubt about the evaluation of the
adverse event. In addition, each investigator will be required
to complete and sign a prespecified form and to send it to the
promoter center, along with any available clinical documen-
tation to certify the adverse event.Patients will be advised to contact the investigator
immediately after the occurrence of any adverse event,
without waiting for the next scheduled visit and before
stopping the assigned treatment.Statistical analyses
Categorical variables will be reported as percentages,
whereas continuous variables expressed as means ± SD
or medians and interquartile ranges according to their
distr ibution, which wil l be tested with the
Kolmogorov-Smirnov test. Differences between the
percentages will be assessed by using the χ2 test or by
Fisher exact test. The Student t test and Pearson
correlation analyses will be used for normally distributed
continuous variables. Appropriate nonparametric tests
will be used for all other variables. Multiple linear
regression analysis will be used to assess independent
predictors of the absolute annual changes in eGFR,
whereas the multiple logistic regression analysis will be
used to identify factors associated with the rapid decline
in kidney function. To evaluate the changes in eGFR
stages over the trial, ordinal logistic regression models
will be used. The outcomes will be assessed at 2 follow-up
times (at 6 and 12 months) simultaneously via regression
models for longitudinal data, using a random
subject-dependent intercept to take account of the
dependence of replicate measurements on the same
subjects.
An interim analysis will be performed on the primary
end point when 33% of patients will have been
randomized and completed the 12-month follow-up.
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ended using symmetric stopping boundaries at if
P b .001 at interim.
Statistical significance will be determined at a value of
P b .05. The analyses will be performed with the SPSS
software version 20 for Windows (SPSS, Chicago, IL) and R
v. 3.0.2 for Linux (© The R Foundation, Vienna, Austria).Calculation of the sample size of the trial
The minimum sample size of the trial is estimated on data
from previous studies that have estimated an annual
reduction of GFR in patients with T2DM of about 2.5 mL/
min per 1.73 m2.42 On this basis and assuming a protective
effect of aspirin of about 20% on the progression of eGFR
with a standard deviation (DS) of 1.5, it is estimated to
include a minimum of 380 patients (190 treated with aspirin
and 190 placebo) to have a 90% chancewith a probability of
error of type I α = .05 to identify a significant reduction in
theprimary endpoint.With anexpected 10%dropout rate at
follow-up, the final sample to be included in the trial will be
of 418 patients (209 for each arm of treatment).
The planned sample size will allow us to achieve an
80% power for a correlation (in absolute value) of 0.14 or
more between urinary 11-dehydro-TxB2 and renal func-
tion modifications.Funding
The trial will be supported by an unrestricted grant from
Bayer SpA for the production of aspirin and placebo. Bayer
SpAwill not be involved in any phase of patients' recruitment
or data analysis and interpretation. Thus, the authors are
solely responsible for the design and conduct of this study, all
study analyses, and drafting and editing of the manuscript.Summary
The LEDA trial will be the first multicenter, double-blind,
placebo-controlled trial to examine whether treatment
with aspirin (100 mg daily) may beneficially affect kidney
function in adult patients with T2DM by lowering the
annual decline of eGFR. The trialwill also examinewhether
the potential renoprotective effects of aspirin might be
partly due to its inhibition of TxB2 production.Disclosures
The authors have no conflict of interest to declare
related to this study.References
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